摘要
目的分析经冠状动脉或静脉注射替罗非班对急性心肌梗死经皮冠状动脉介入(PCI)治疗患者的临床疗效。方法选取2016年1月—2021年12月收治的急性心肌梗死286例,均接受PCI治疗。按照给药方式不同分为对照组130例和观察组156例。对照组经静脉注射替罗非班,观察组经冠状动脉注射替罗非班。比较2组临床疗效、心肌梗死溶栓治疗(TIMI)血流分级、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)及舒张早期心室充盈速度最大值/舒张晚期心室充盈速度最大值比值(E/A)及心血管不良事件发生情况。结果观察组临床总有效率高于对照组(P<0.01)。治疗后,2组TIMI血流分级比较差异有统计学意义(P<0.01)。治疗后,2组LVEDD、LVESD水平均较治疗前下降,E/A>1患者比例较治疗前上升;且观察组LVEDD、LVESD水平均低于对照组,E/A>1患者比例高于对照组(P<0.05)。观察组心血管不良事件总发生率低于对照组(P<0.01)。结论急性心肌梗死患者PCI治疗后,经冠状动脉注射替罗非班临床效果显著,可有效改善TIMI血流分级,缓解左心室重塑,恢复灌注水平,且安全性高。
Objective To analyze the clinical efficacy of Tirofiban via coronary or intravenous injection in patients with acute myocardial infarction(AMI)undergoing percutaneous coronary intervention(PCI)treatment.Methods A total of 286 patients with AMI who were admitted from January 2016 to December 2021 were selected and all received PCI treatment.According to different administration methods,they were divided into control group(n=130)and observation group(n=156).The control group received intravenous injection of Tirofiban,while the observation group received coronary injection of Tirofiban.The clinical efficacy,thrombolytic therapy for myocardial infarction(TIMI)blood flow classification,left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)and the ratio of maximum early diastolic ventricular filling velocity to maximum late diastolic ventricular filling velocity(E/A)and incidence of adverse events of the two groups were compared.Results The total clinical effective rate of the observation group was higher than that of the control group(P<0.01).After treatment,there were significant differences in TIMI blood flow classification between the two groups(P<0.01).After treatment,the levels of LVEDD and LVESD in the two groups were significantly decreased compared with those before treatment,and the proportion of patients with E/A>1 increased compared with that before treatment;the levels of LVEDD and LVESD in the observation group were lower than those in the control group,and the proportion of patients with E/A>1 was higher than that in the control group(P<0.05).The total incidence of cardiovascular adverse events in the observation group was lower than that in the control group(P<0.01).Conclusion After PCI treatment in patients with AMI,Tirofiban via coronary injection has a significant clinical effect,can effectively improve TIMI blood flow classification,relieve left ventricular remodeling,restore perfusion level,and has high safety.
作者
刘曙杰
陈儒
孙立娜
史超
于向志
LIU Shu-jie;CHEN Ru;SUN Li-na;SHI Chao;YU Xiang-zhi(Department of Cardiology,People's Hospital of Chengyang District,Qingdao,Shandong 266109,China)
出处
《解放军医药杂志》
CAS
2022年第9期34-37,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
山东省医药卫生科技发展计划项目(2015WS136)。
关键词
心肌梗死
经冠状动脉介入
替罗非班
心室功能
左
Myocardial Infarction
Percutaneous coronary intervention
Tirofiban
Ventricular function,left
